2 years on Dutasteride/Minox, so much hair loss, not sure where to go from here
    Finasteride/Dutasteride 1/11/2026

    From the encyclopedia
    Dutasteride β†’

    5-alpha reductase inhibitor that blocks both enzyme types, a stronger DHT blocker than finasteride

    Minoxidil β†’

    Vasodilator used on the scalp and, at low doses, as a tablet

    Finasteride β†’

    Popular 5-alpha reductase inhibitor that lowers DHT, taken as a pill or used topically

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    πŸ’Š Dutasteride (oral) 2 years
    πŸ’§ Minoxidil (topical) once a day 10 years
    πŸ’Š Finasteride (oral) 10 years
    πŸ’§ Microneedling (topical) 1.5 dermaroller once a week 2 months
    the tone is 😞 negative with no growth results.

    Other terms

    The user has been experiencing increased hair loss despite using Dutasteride, Minoxidil, and microneedling, and is considering switching back to Finasteride. They are exploring other options like hair transplants, oral Minoxidil, and red light therapy but are concerned about side effects and effectiveness.
    View this post in the Community β†’

    Similar Community Posts Join

    6 / 6 results

    Related Research

    6 / 6 results

      research Safety concerns when using novel medications to treat alopecia

      23 citations , October 2018 in “Expert Opinion on Drug Safety”
      This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.

      research Management of androgenetic alopecia: a review

      January 2021 in “International Journal of Research in Dermatology”
      This source reviews treatments for androgenetic alopecia, highlighting that combining therapies generally improves effectiveness over single treatments, and discusses emerging drug-assisted delivery techniques aimed at increasing the efficiency of conventional drugs like minoxidil and finasteride.

      research Androgenetic alopecia: An update

      July 2023 in “JAAD International”
      This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.